

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ahlsson Anders	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Atrial fibrillation symposium speakers fee year 2008: 500 Euro (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Swedish Society of Medicine : Financial support for studies (2016-2017) - Örebro university hospital Research committee : Financial support for studies years 2008-2013 (2016-2017) - Vingmed / Estech : Microwave ablation study year 2008: 5000 Euro (2016-2017)
Alfonso Manterola Fernando	Nothing to be declared (2016-2017)
Banning Adrian Paul	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : coronary stents (2016) - Medtronic : coronary stents (2016) - Abbott Vascular : coronary stents (2016) - Philips : intravascular ultrasound (2016) - Miracor : PICSO (2016) - Philips : IVUS (2017) - Abbott : stents (2017) - Boston Scientific : stents (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : interventional research (2016) - Boston Scientific : stents (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Benedetto Umberto	Nothing to be declared (2016-2017)
Byrne Robert	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Vascular intervention (2016-2017) - Biotronik : Vascular intervention (2016-2017) - B.Braun : Vascular intervention (2016-2017) - Micell Technologies : Vascular intervention (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - HeartFlow : Imaging analysis (2016) - Boston Scientific : Vascular intervention (2016-2017) - Celonova : Vascular intervention (2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016) - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016) - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Falk Volkmar	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Dr. Falk reports grants and other from Abbott, grants and other from Medtronic, grants and other from Edwards, outside the submitted work; and Advisory board: : Educational Grant and other (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : heart valves (2016) - Edwards Lifesciences : heart valves (2016) - Medtronic : heart valves (2016) - Aesculap : minimally invasive mitral surgery (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : Imaging (2016) - Heartware : LVAD (2016) - SJM : VAD Therapy (2016)
Head Stuart	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - medistim : Graft flow measurement (2016)
Juni Peter	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Juni Peter	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)
Kastrati Adnan	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I have benefitted licence fees related to own patents on drug-eluting stents (2016) - I have benefitted licence fees related to own patents on drug-eluting stents. (2017)
Koller Akos	<p>Nothing to be declared (2016-2017)</p>
Kristensen Steen Dalby	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Aspen : anti-thrombotics fondaparinux (2016) - Bayer AG : anti-thrombotics rivaroxiban (2016) - Astra Zeneca : anti-thrombotics Ticagrelor (2016) - BMS/Pfizer : apixaban (2017) - Bayer : rivaroxiban (2017) - Astra Zeneca : ticagrelor (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : ticagrelor (2016)
Neumann Franz Josef	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant Therapy (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Neumann Franz Josef	<ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulant therapy (2016-2017) - Pfizer : Anticoagulant therapy (2016-2017) - Bayer Healthcare : Anticoagulant therapy (2016-2017) - Bristol Myers Squibb : Anticoagulant therapy (2016-2017) - Astra Zeneca : Antiplatelet therapy (2016-2017) - Boston Scientific : Interventional cardiology (2016-2017) - Edwards Lifesciences : Transcatheter valves (2016-2017) - Medtronic : Transcatheter valves (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulant therapy (2016-2017) - Novartis : Heart failure (2016-2017) - Pfizer : Heart failure (2016-2017) - GlaxoSmithKline : Heart failure (2016-2017) - Biotronik : Interventional Cardiology (2016-2017) - Abbott Vascular : MitraClip (2016-2017) - Edwards Lifesciences : Transcatheter Valves (2016-2017) - Medtronic : Transcatheter Valves (2016-2017)
Niebauer Josef	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : cardio-metabolic (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Angelini : Lipids (2016) - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Menarini : CAD- hypertension (2016-2017) - Novartis : hypertension (2016-2017) - Abbott : lipids (2016-2017) - Amgen : lipids (2016-2017) - Sanofi Aventis : Lipids (2016-2017) - Lilly : Lipids (2016-2017) - Unilever : lipids (2016-2017) - Merck Sharp & Dohme : lipids (2016-2017) - Vianex : lipids (2016-2017) - Galenica : Lipids (2016-2017) - Teva Pharmaceutical Industries : lipids, hypertension (2016-2017) - Bayer Healthcare : Thrombosis (2016-2017) - Edwards Lifesciences : aortic stenosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Novo-Nordisk : diabetes (2017) - Unipharma : hypertension-thrombosis (2017)
Seferovic Petar	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : coronary disease, heart failure (2016-2017) - Boehringer-Ingelheim : heart failure, hypertension (2016-2017) - Pfizer : heart failure, hypertension (2016-2017) - Berlin Chemie AG : heart failure, hypertension (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2016-2017)
Sibbing Dirk	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelets (2016-2017) - Daiichi Sankyo : Antiplatelets (2016-2017) - Eli Lilly : Antiplatelets (2016-2017) - Bayer Healthcare : NAOCS (2016-2017) - Pfizer : NOACS (2016-2017) - Roche Diagnostics : Platelet function testing (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Platelets (2016-2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sousa Uva Miguel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Dabigatran (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Ticagrelor (2016)</p>
Stefanini Giulio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Edwards Lifesciences : Interventional Cardiology (2016) - Boston Scientific : Interventional Cardiology (2016-2017) - B.Braun : Interventional Cardiology (2016-2017) - Biosensors : Interventional cardiology (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Boston Scientific : Interventional Cardiology (2016-2017)</p>
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Bracco Pharmaceutical : General Cardiology (2016) - Boston Scientific : General Cardiology (2016-2017) - Abbott : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Yadav Rashmi	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Advisory Board Fee (2017) - Edwards Lifesciences : Speaker fees and consultancy (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Travel grants (flight, hotel and occasionally registration fee) from Maquet, Edwards and Medtronic to attend annual meetings of professional societies such as EACTS, ISMICS, STS to the value of less than £10,000 (2016-2017)
Zembala Michael	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Symetis SA : TAVI valves - proctor for TA-TF (2016)

2018 ESC/EACTS Guidelines on myocardial revascularization - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zembala Michael	<ul style="list-style-type: none"> - Boston Scientific : TAVI valves - proctor for TA-TF (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Atricure : Proctor for AF ablation (2016-2017) - Abbott : proctor for Heart Mate 3 LVAD (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017)
Achenbach Stephan	Nothing to be declared (2017)
Addad Faouzi	Nothing to be declared (2017)
Agewall Stefan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet treatment (2017)
Akdemir Ramazan	Nothing to be declared (2017)
Aladashvili Alexander	Nothing to be declared (2017)
Andreotti Felicita	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Actelion : antiplatelet therapy (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Andreotti Felicita	<ul style="list-style-type: none"> - Pfizer : apixaban (2017) - BMS : apixaban (2017) - Boehringer Ingelheim : dabigatran (2017) - Amgen : dyslipidaemia (2017) - Daiichi Sankyo : edoxaban (2017) - Bayer Schering Pharma : rivaroxaban (2017) - Medscape : stroke prevention in atrial fibrillation (2017)
Bajraktari Gani	Nothing to be declared (2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Education courses on rotational atherectomy (2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2017)
Baumbach Andreas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Drugs (2017) - Abiomed : LV Assist (2017) - Abbott Vascular : Stents (2017) - Microport : Stents (2017) - Sinomed : Stents (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Baumbach Andreas	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott Vascular : Stents (2017)
Becker David	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : NOAC (2017) - Merck Sharp & Dohme : NOAC (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Sanofi Aventis : PCSK9 I (2017)
Beleslin Branko	1- Financial Declaration E - Research funding (personal). - Ministry of Science and Education of the Republic of Serbia : grant number 41022 (2017)
Brophy James	Nothing to be declared (2017)
Bueno Hector	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : Apixaban (2017) - Bristol Myers Squibb : Apixaban (2017) - Bayer : Aspirin, rivaroxaban (2017) - MEDSCAPE-the heart.org : Inespecific (2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) - Astra Zeneca : Ticagrelor (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Ferrer Internacional : Trinomia (polypill) (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2017) E - Research funding (personal). <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017) 2- Other Positions of Influence <ul style="list-style-type: none"> 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. <ul style="list-style-type: none"> - VP elect. Spanish Society of Cardiology FAHA (2017)
Bunc Matjaz	Nothing to be declared (2017)
Calvert Patrick Andrew	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : 2017 Acute Coronary Syndrome (Speaker at symposium) (2017) - Sanofi Aventis : Alirocumab - single advisory board meeting 2016 (2017) - Occlutech : Proctor for paravalvular leak closure 2017-8 (2017) - St Jude Medical : Speaker at training meeting for structural heart disease 2016 (2017)
Capodanno Davide	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulant drugs (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Capodanno Davide	<ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulant drugs (2017) - Astra Zeneca : Antiplatelet drugs (2017) - Abbott : Intravascular imaging (2017) - Cordis : PCI (2017)
Chettibi Mohamed	Nothing to be declared (2017)
Davierwala Piroze M	Nothing to be declared (2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Dudek Dariusz	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medapp : shareholder (2017) - Philips : speaker fee, advisory boards, investigator (2017) - Sanofi Aventis : speaker fee, advisory boards, investigator (2017) - TMS sp. z.o.o. : speaker fee, advisory boards, investigator (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dudek Dariusz	<ul style="list-style-type: none"> - Accord Healthcare : speaker fee, advisory boards, investigator (2017) - Cardinal Health Poland Sp. z.o.o : speaker fee, advisory boards, investigator (2017) - Medaccess : speaker fee, advisory boards, investigator (2017) - Teleflex Polska Sp. z.o.o : speaker fee, advisory boards, investigator (2017) - Astra Zeneca : speaker fee, advisory boards, investigator. (2017) - Boston Scientific : speaker fee, advisory boards, investigator. (2017) - Edwards Lifesciences : speaker fee, advisory boards, investigator. (2017) - Medtronic : speaker fee, advisory boards, investigator. (2017) - Biotronik : speaker fee, advisory boards, investigator. (2017) - Terumo Inc : speaker fee, advisory boards, investigator. (2017) - GE Healthcare : speaker fee, advisory boards, investigator. (2017) - Bracco Pharmaceutical : speaker fee, advisory boards, investigator. (2017) - Abbott Laboratories : speaker fee, advisory boards, investigator. (2017) - Balton : speaker fee, advisory boards, investigator. (2017) - Stentys : speaker fee, advisory boards, investigator. (2017) - Comesa Polska : speaker fee, advisory boards, investigator. (2017) - ProCardia Medical : speaker fee, advisory boards, investigator. (2017) - SIS Medical : speaker fee, advisory boards, investigator. (2017) - Aesculap Chifa : speaker fee, advisory boards, investigator. (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Duplyakov Dmitry	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : apixaban (2017) - Boehringer-Ingelheim : Dabigatran (2017) - Berlin Chemie AG : Ranolazine (2017) - Bayer Healthcare : Rivaroxaban (2017) - Astra Zeneca : Ticagrelor (2017)
Eftychiou Christos	Nothing to be declared (2017)
Eha Jaan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : simulators in cardiology, DAPT duration studies (2017)
Freemantle Nick	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - University Hospitals NHS Foundation Trust : NHS Provider (2017) E - Research funding (personal). - Allergan : Device (2017) - Novo-Nordisk : Diabetes (2017) - Sanofi Aventis : Diabetes, RA (2017) - Takeda Pharmaceuticals : Oncology (2017) - Ipsen : Oncology (2017) - Biogen : RA (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Freemantle Nick	2- Other Positions of Influence 2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Honorary contract University Hospitals Birmingham NHS Foundation Trust, UK. (2017)
Funck-Brentano Christian	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Guerbet : Cardiac safety of a contrast agent (2017) - Inventiva : Cardiac safety of a new chemical entity developed for systemic sclerosis (2017) - Intracellular Therapies USA : Cardiac safety of an experimental non-cardiovascular drug (2017) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2017) - Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2017) - MMV (CH) : Cardiac Safety of two antimalarial drugs (2017) - Actelion : Comments on the cardiac pharmacodynamic results of a phase I study of a new chemical entity (2017) - Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology (2017) 2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Member of the Committee for Practice Guidelines - ESC (2006-2012) Member of the Task Force on the Guidelines on Stable Coronary Artery Diseases (to be issued in 2019) (2017)
Gaemperli Oliver	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE Healthcare : Imaging (2017)
Ghazzal Ziyad	Nothing to be declared (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Gielen Stephan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : antithrombotic therapy - advisory board membership, lecture honoraria (2017) - Novartis : Heart failure therapy (lecture honoraria, travel support) (2017) - Amgen Inc : PCSK9-inhibitors - lecture honoraria (2017) - Daiichi Sankyo : Travel support for ESC congress participation (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : ANNEXA 4 Study - Dr. Härtel (2017) - Biotronik : BLOWDOWN Study (2017) - Daiichi Sankyo : ETNA-VTE Registry & EMIT-AF-VTE Registry - Dr. Härtel (2017) - B. Braun : LOCOMOTIVE & CONSEQUENT ALL COMERS Registry (2017) - CorVia : REDUCE LAP-HF TRIAL III/ Corvia Medical (2017) - Amgen Inc : REPATHA Register - Dr. Härtel (2017) - Novartis : Support for heart failure nurse training (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - National Coordinator for Prevention for Germany within the EAPC network Please Note: Research funding (departmental or institutional) from healthcare industry is also listed under B. (2017)
Gilard Martine	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : medication (2017) - Medtronic : TAVI (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Gilard Martine	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : medication (2017) - Terumo Inc : OCT/stent (2017) - Abbott Vascular : Stent (2017) - Edwards Lifesciences : TAVI (2017) - GE Healthcare : Technology (2017)
Glineur David	<p>Nothing to be declared (2017)</p>
Gorenek Bulent	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2017) - Daiichi Sankyo : Anticoagulation (2017) - Pfizer : Anticoagulation (2017)
Gudnason Thorarinn	<p>Nothing to be declared (2017)</p>
Haasenritter Joerg	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - I am member of the German College of General Practitioners and Family Physicians and have been involved in the development of several German Guidelines: - Chest pain in primary care (http://www.awmf.org/leitlinien/detail/II/053-023.html), - National Disease Management Guideline on stable coronary heart disease (http://www.leitlinien.de/nvl/khk), - Cardiovascular prevention in primary care (http://www.awmf.org/leitlinien/detail/anmeldung/1/II/053-024.html). (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Haude Michael	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Lilly : anti platelet therapy (2017) - Abbott : BVS, MitraClip (2017) - Volcano : IVUS (2017) - Biotronik : PCI (2017) - Cardiac Dimensions : structural heart interventions (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : scaffold (2017) - Biotronik : scaffold (2017) - Cardiac Dimensions : structural heart intervention (2017)
Henderson Robert Anthony	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Creavo Medical Technologies : Novel technology to triage patients with chest pain in accident and emergency departments (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Henderson Robert Anthony	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member, NICE Acute Coronary Syndromes Guideline Development Group, 2007-9 Clinical Advisor, NICE Stable Angina Guideline Development Group, 2009-11 Member, NICE Stable Angina Topic Expert (Quality Standards) Group, 2011-2 Deputy Chair, NICE STEMI Guideline Development Group, 2011-3 Member, Advisory Group for Management of Stable Angina Evidence Update, 2012 (Evidence Update 23: Management of Stable Angina) Specialist Adviser to NICE Interventional Procedures Guidance Programme: Optical Coherence Tomography IPG481 2013; Patent Foramen Ovale 2013 IPG 472. Specialist committee member for acute coronary syndromes, NICE Quality Standard Advisory Committee (QSAC) 2013-14 Expert Adviser, NICE Medical Technologies Advisory Committee (MTAC) on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography, 2015-16. Topic Expert, NICE Surveillance report 2016 – Unstable angina and NSTEMI (2010) NICE guideline CG94 and Myocardial infarction with ST-segment elevation (2013) NICE guideline CG167. Expert Adviser, NICE Centre for Clinical Practice, 2016-19. Chair, Trial Steering Committee, FAMOUS-NSTEMI, 2012-8 Chair, Trial Steering Committee, ERIC-PPCI 2014-18 (2017)
Hofma Sjoerd H	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : cardiovascular (2017)
Ibanez Borja	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO drugs or products involved. (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - My center (CNIC) is a non-profit organization that receives royalties for the sales of a polypill (trinomia) which is constituted by aspirin-ramipril-simvastatin. I am not involved in the scientific development and have NO direct interest (no personal benefits). (2017)
Ibrahimov Firdovsi	<p>Nothing to be declared (2017)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Infante de Oliveira Eduardo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Terumo Inc : Coronary (2017) - Medtronic : Coronary and non-coronary (2017) - Boston Scientific : Left Atrial Appendage (2017) - St Jude Medical : Left Atrial Appendage (2017) - Abbott Vascular : Mitral Intervention (2017)
Iung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017) - Edwards Lifesciences : Heart valve prostheses (2017)
Jeger Raban	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - B.Braun : BASKET-SMALL 2 (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Swiss Society of Cardiology Working Group Interventional Cardiology (2017)
Jeppsson Anders	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astrazeneca : Cardiovascular (2017) - LFB : Haemostasis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Jeppsson Anders	<ul style="list-style-type: none"> - Octapharma : Haemostasis (2017) - CSL Behring : Haemotysis (2017) - XVIVO : Perfusion (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017)
Kala Petr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : adjuvant pharmacology (2017) - Boston Scientific : interventional cardiology (2017) - Terumo Inc : interventional cardiology (2017) - Amgen : research drug (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Zoll Medical : interventional cardiology (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Biosensors : interventional cardiology (2017)
Kanakakis Ioannis-Georgios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2017) - Beringer : Antithrombotics (2017) - Novartis : Heart failure (2017)
Katrtsis Demosthenes	<p>1- Financial Declaration</p> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Oxford University Press : Cardiology Textbook (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katrtsis Demosthenes	D - Research funding (departmental or institutional) from healthcare industry. - Medtonic : Electrophysiology (2017) - Boston Scientific : Interventional Cardiology (2017)
Kedev Sasko	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boston Scientific : Speaker fees (2017) - Medtronic : Speaker fees (2017) - Terumo Inc : Speaker fees (2017) - Meril : Speaker fees (2017)
Kerimkulova Alina	Nothing to be declared (2017)
Kibarskis Aleksandras	Nothing to be declared (2017)
Knuuti Juhani	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)
Kolh Philippe H	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet agents (2017)
Kovar Frantisek	Nothing to be declared (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Leite-Moreira Adelino	Nothing to be declared (2017)
Lund Lars	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2017) - Sanofi Aventis : Heart Failure (2017) - Astrazeneca : Heart Failure (2017) - Viforpharma : Heart Failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Heart Failure (2017) - Novartis : Heart Failure (2017) - Relypsa : Heart Failure (2017)
Magdy Ahmed	Nothing to be declared (2017)
Maisano Francesco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Perifect : Arrhythmias (2017) - Transseptal Solutions : Arrhythmias (2017) - 4Tech Cardio : Cardioracic Surgery (2017) - Mitraltech : Cardioracic Surgery (2017) - Xeltis : Valvular Heart Disease (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Maisano Francesco	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Cardiotoracic Surgery (2017) - Edwards Lifesciences : Cardiotoracic Surgery (2017) - Medtronic : Cardiotoracic Surgery (2017) - St. Jude : Cardiotoracic Surgery (2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiotoracic Surgery (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiovascular Surgery (2017) - Medtronic : CoreValve (2017) - Abbott : Mitraclip (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - 4Tech, Transeptal Solution, Mitraltech (2017)
Mehilli Julinda	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : coronary (2017) - Biotronik : coronary (2017) - Terumo Inc : coronary (2017) - Abbott Vascular : coronary (2017) - Bristol Myers Squibb : coronary (2017) - Boston Scientific : structural (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mehilli Julinda	<ul style="list-style-type: none"> - Edwards Lifesciences : structural (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Abbott Vascular : coronary (2017) - Edwards Lifesciences : structural (2017) E - Research funding (personal). <ul style="list-style-type: none"> - DZHK : invasive cardiology (2017)
Metzler Bernhard	Nothing to be declared (2017)
Montalescot Gilles	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : cardiovascular disease (2017) - Amgen : cardiovascular disease (2017) - Bayer : cardiovascular disease (2017) - Boston Scientific : cardiovascular disease (2017) - Medtronic : cardiovascular disease (2017) - Pfizer : cardiovascular disease (2017) - Servier : cardiovascular disease (2017) - Actelion : cardiovascular disease (2017) - Sanofi Aventis : cardiovascular disease (2017) - Menarini : cardiovascular disease (2017) - Lilly : cardiovascular disease (2017) - WebMD : cardiovascular disease (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Cardiovascular Research Foundation : cardiovascular disease (2017) - Europa : cardiovascular disease (2017) - Lead-Up : cardiovascular disease (2017) - Novo-Nordisk : cardiovascular disease (2017) - Elsevier : cardiovascular disease (2017) - MSD : cardiovascular disease (2017) - American College of Cardiology : cardiovascular disease (2017) - Astrazeneca : cardiovascular disease (2017) - Daiichi-Sankyo : cardiovascular disease (2017) - Boehringer Ingelheim : cardiovascular disease (2017) - Bristol-Myers Squibb : cardiovascular disease (2017) - Beth Israel Deaconess Medical : cardiovascular disease (2017) - TIMI Study Group : cardiovascular disease (2017) - Brigham Women's Hospital : cardiovascular disease (2017) - The Mount Sinai School : cardiovascular disease (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : cardiovascular disease (2017) - Bayer : cardiovascular disease (2017) - Boehringer-Ingelheim : cardiovascular disease (2017) - Pfizer : cardiovascular disease (2017) - Sanofi Aventis : cardiovascular disease (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Bristol Myers Squibb : cardiovascular disease (2017) - MSD : cardiovascular disease (2017) - Astrazeneca : cardiovascular disease (2017) - ICAN : cardiovascular disease (2017) - Fédération Francaise de Cardiologie : cardiovascular disease (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : Apixaban (2017) - Medtronic : Corevalve (2017) - Bayer AG : Rivaroxaban (2017) - Astra Zeneca : Ticagrelor (2017)
Mot Stefan	Nothing to be declared (2017)
Motreff Pascal	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : BVS (2017) - Terumo Inc : OCT imaging (2017) - saint Jude medical : OCT imaging (2017)
Niemela Matti Jaakko	Nothing to be declared (2017)
Ojeda Pinedo Soledad	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Spanish Society of Cardiology : Speaker fees (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pagano Domenico	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Secretary General EACTS International Director Board Society Thoracic Surgeon (US) (2017)
Parkhomenko Alexander	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - BHFZ : corvitin (2017) - Sanofi Aventis : enoxaparin (2017) - Servier : preductal (2017) - Bayer Healthcare : rivaroxaban (2017) - Astra Zeneca : ticagrelor (2017) D - Research funding (departmental or institutional) from healthcare industry. - European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2017)
Peace Aaron J	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : anticoagulation (2017) - Bayer AG : anticoagulation (2017) - Astra Zeneca : antiplatelet (2017) - Daiichi Sankyo : antiplatelet and anticoagulation (2017) - Biosensors : drug eluting stents and balloons (2017)
Pereira Bruno	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Merck Sharp & Dohme : Speaker fee (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pereira Bruno	- Menarini : Speaker fees (2017)
Petronio Anna Sonia	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : MitraClip (2017) - Boston Scientific : TAVI (2017) - Medtronic : TAVI (2017)
Piepoli Massimo Francesco	Nothing to be declared (2017)
Popescu Bogdan Alexandru	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE Healthcare : Imaging (2017) 2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - President-Elect of the Romanian Society of Cardiology (2017)
Postadzhiyan Arman	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : ACS (2017) - Bayer : AF (2017) - Boehringer-Ingelheim : AF (2017) - Pfizer : AF, dyslipidemia (2017) - Amgen : dyslipidemia (2017) - Sanofi Aventis : dyslipidemia (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Romeo Francesco	Nothing to be declared (2017)
Rudzitis Ainars	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Arterial Hypertension (2017) - Berlin Menarini : CAD (2017) - Shire HGT : Fabry disease (2017) - Genzyme : Fabry disease (2017) - Boehringer-Ingelheim : NOACs (2017)
Sadaba Rafael	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Atricure : AF ablation (2017) D - Research funding (departmental or institutional) from healthcare industry. - TIGenix : Myocardial cell regeneration (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Krka Pharma : Arterial Hypertension (2017) - Novartis : Arterial Hypertension, Heart Failure (2017) - Merck Sharp & Dohme : Atherosclerosis (2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017) - Pfizer : General Cardiology (2017)
Silber Sigmund	Nothing to be declared (2017)
Simpson Iain A	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sisakian Hamayak	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : Rivaroxaban (2017) - Servier : Trimetazidine, Ivabradine (2017)
Skoric Bosko	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novartis : Entresto (2017)
Sparv David	Nothing to be declared (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Steigen Terje Kristian	Nothing to be declared (2017)
Stelmashok Valeriy	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : Advisore boar team member (2017)
Tavilla Giuseppe	Nothing to be declared (2017)
Terkelsen Christian Juhl	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abiomed : impella (2017) - Terumo Inc : Radial procedures (2017) - Boston Scientific : rotational atherextomy (2017) - Cardinal health : Sheatless procedures (2017) D - Research funding (departmental or institutional) from healthcare industry. - Terumo Inc : Coronary angiography equipment (2017)
Thiele Holger	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - European Research Foundation FP7 : Cardiogenic shock (2017)
Tousek Petr	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet treatment (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Van Belle Eric	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : FFR (2017) - Philips : FFR/iFR (2017)
Vranckx Pascal	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Edoxaban (2017) - Bayer Healthcare : Rivaroxaban (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Supplier (2017) <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of the Academic Research Consortium (2017)
Widimsky Petr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Antiischemic agents (2017) - Astra Zeneca : Antithrombotic agents (2017) - Bayer : Antithrombotic agents (2017) - Boehringer-Ingelheim : Antithrombotic agents (2017) - Medtronic : Stents (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Wijns William	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Biotronik : device (2017) - Microport : device (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Microport : device (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Co-Director of Euro-PCR, the official annual meeting of EAPCI, since May 2010. Chairman of PCR, since May 2012. Co-Director of PCR Africa, since February 2013. Non executive Board member and co-founder of Argonauts Partners (innovation accelerator). Please note that I have changed positions in 2016: Cardiovascular Center Aalst (Jan till April), sabbatical leave (May till September), NUIG as of October 2016. (2017)
Witkowski Adam	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : bioabsorbable coronary stents (2017) - Terumo Inc : coronary stents (2017) - Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI) (2017) - Medtronic : Evolute aortic valves (TAVI) (2017) - Edwards Lifesciences : Sapien aortic valves (TAVI) (2017)
Witt Nils	Nothing to be declared (2017)
Xuereb Robert G	Nothing to be declared (2017)

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : afib (2017) - Pfizer : Afib (2017)
Zavatta Marco	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer Healthcare : Oral anticoagulants (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2016-2017) - Novartis : Hypertension (2016-2017) - Boehringer-Ingelheim : Oral anticoagulation (2016-2017) - Bayer Healthcare : Oral anticoagulation (2016-2017) - Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet treatment (2016-2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Educational courses on FFR (2016) - Boston Scientific : Education courses on rotational atherectomy (2016-2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : BVS (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Pfizer : Apixaban (2016-2017) - Bristol Myers Squibb : Apixaban (2016-2017) - Bayer : Aspirin, rivaroxaban (2016-2017) - MEDSCAPE-the heart.org : Inespecific (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Ferrer Internacional : Trinomia (polypill) (2016-2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - BMS : CV013-011 - STANDUP-AHF trial (2016-2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - FAHA (2016) - VP elect. Spanish Society of Cardiology FAHA (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Merck Serono : Bisoprolol-Amlodipine (2016-2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2016-2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016) - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia , (2016-2017) - Novartis : HF (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Novartis : HF (2016-2017) - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016) - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	<ul style="list-style-type: none"> - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Fitzsimons Donna	Nothing to be declared (2016-2017)
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016) - GE Healthcare : Imaging (2017)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016) - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
Iung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016-2017) - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017)
Juni Peter	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Bayer Vital : Xarelto-NOAK (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016-2017) - Philips : MRT (2016-2017)
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Echo course (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> - Servier : Ischemic Heart Disease (2016-2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : Structural disease (2016) - Bayer : NOAC (2016-2017)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Bayer Healthcare : DOAC (2016) - Boston Scientific : devices (2016-2017) - Medtronic : devices (2016-2017) - Biotronik : devices (2016-2017) - Abbott : devices (2017) - Llvanova : devices (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2016-2017) - Novartis : Honoraria (2016-2017) - Bayer AG : Honoraria (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : devices (2016) - BioControl : devices (2016) - Pfizer : lipids (2016) - Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017) - Respicardia : devices (2016-2017) - Novartis : heart failure (2016-2017) - Cardiorentis : heart failure (2016-2017) - Berlin Chemie AG : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - Vifor Pharma ltd : heart failure (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - DC Device : devices (2016) - Cardioentis : heart failure (2016) - Respicardia : anticoagulant (2016-2017) - BioControl : devices (2016-2017) - Novartis : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - National Institute of Health : heart failure (2017) - European Union grant : heart failure, prevention (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Angelini : Lipids (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Menarini : CAD- hypertension (2016-2017) - Novartis : hypertension (2016-2017) - Abbott : lipids (2016-2017) - Amgen : lipids (2016-2017) - Sanofi Aventis : Lipids (2016-2017) - Lilly : Lipids (2016-2017) - Unilever : lipids (2016-2017) - Merck Sharp & Dohme : lipids (2016-2017) - Vianex : lipids (2016-2017) - Galenica : Lipids (2016-2017) - Teva Pharmaceutical Industries : lipids, hypertension (2016-2017) - Bayer Healthcare : Thrombosis (2016-2017) - Edwards Lifesciences : aortic stenosis (2017) - Novo-Nordisk : diabetes (2017) - Unipharma : hypertension-thrombosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016) - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016-2017) - Novartis : Arterial Hypertension, Heart Failure (2016-2017) - Merck Sharp & Dohme : Atherosclerosis (2016-2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2016-2017)
Simpson Iain A	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2016-2017)
Sousa Uva Miguel	Nothing to be declared (2017) 1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Dabigatran (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Ticagrelor (2016)
Windecker Stephan	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016) - Boston Scientific : General Cardiology (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) - Bayer : afib (2017) - Pfizer : Afib (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)